Evidence map›Paper›PMID 36870944›Full record

Trial reportBMC anesthesiology2023

Real-time evaluation of the independent analgesic efficacy of dexmedetomidine.

XiaoHua Wang, SiYuan Zhang, Chunxiu Wang, Yi Huang, Hao Wu, Guoguang Zhao, TianLong Wang

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC anesthesiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

XiaoHua Wang *Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
SiYuan Zhang *Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
Chunxiu WangDepartment of Evidence-Based Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China.
Yi HuangNational Clinical Research Center for Geriatric Disorders, Beijing, China.
Hao WuNational Clinical Research Center for Geriatric Disorders, Beijing, China.
Guoguang ZhaoNational Clinical Research Center for Geriatric Disorders, Beijing, China.
TianLong WangDepartment of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China. w_tl5595@yeah.net.ORCID 0000-0003-1636-0142
Capital Medical University · CNNational Clinical Research Center for Digestive Diseases · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDexmedetomidine has analgesic properties, but the intraoperative analgesic effect of dexmedetomidine is often masked by the effects of other general anaesthetics. Therefore, the degree to which it reduces intraoperative pain intensity remains unclear. The objective of this double-blind, randomised controlled trial was to evaluate the independent intraoperative analgesic efficacy of dexmedetomidine in real-time.

methodsThis single-centre study enrolled 181 patients who were hospitalised for below-knee orthopaedic surgeries between 19 January 2021 to 3 August 2021 were eligible for this is single-centre study. Peripheral neural block was performed on patients scheduled for below-knee orthopaedic surgeries. Patients were randomly assigned to the dexmedetomidine or midazolam group and were intravenously administered with 1.5 µg kg

resultsOn Kaplan-Meier survival analysis, the defined nociception index target was attained in 95.45% and 40.91% of patients receiving dexmedetomidine and midazolam, respectively. Log-rank analysis revealed that the dexmedetomidine group attained the nociception index target significantly faster and the median attainment time of the nociception index target in the dexmedetomidine group was 15 min. Dexmedetomidine group was associated with a significantly lower incidence of hypoxemia. There was no significant difference in blood pressure between the dexmedetomidine and midazolam groups. Further, the dexmedetomidine group had a lower maximum visual analogue scale score and lower analgesic consumption postoperatively.

conclusionsDexmedetomidine has independent analgesia and systemically administered as an adjuvant agent has better analgesic efficacy than midazolam without severe side effects.

trial registrationclinicaltrial.gov Registry Identifier: NCT-04675372.Registered on 19/12 /2020.

Indexed as

AnalgesiaDexmedetomidineAnalgesicsHumansMidazolamPainAnalgesicsDexmedetomidineMidazolamAnalgesicsDexmedetomidineIOC2, qNOXNociception index

Identifiers

PMID36870944
PMCPMC9985296
OpenAlexW4323047217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.